enzastaurin + gemcitabine + rituximab + oxaliplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Large Cell, Diffuse
Conditions
Lymphoma, Large Cell, Diffuse
Trial Timeline
Feb 1, 2007 → Nov 1, 2012
NCT ID
NCT00436280About enzastaurin + gemcitabine + rituximab + oxaliplatin
enzastaurin + gemcitabine + rituximab + oxaliplatin is a phase 2 stage product being developed by Eli Lilly for Lymphoma, Large Cell, Diffuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00436280. Target conditions include Lymphoma, Large Cell, Diffuse.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00436280 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Large Cell, Diffuse